

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02 Issue Date: 10/08/15 Rev. No: 07 LAB 184</b>
---	-----------------------------------	---

## **Accreditation No: LAB 184**

**Awarded to**

**Prime Health (Pvt.) Ltd., Pakistan.  
1<sup>st</sup> Floor, 30 East, Royal Plaza, Fazal-e-Haq Road, Blue Area,  
Islamabad 44000, Pakistan.**

The scope of accreditation is in accordance with the standard specifications outlined in the following page(s) of this document. The accredited scope shall be visible and legible in areas such as customer service, sample-receiving section etc and shall not mislead its users.

The accreditation was first time granted on **17-10-2019** by Pakistan National Accreditation Council.

The laboratory complies with the requirements of **ISO/IEC 17025:2017**.

The accreditation requires regular surveillance, and is valid until **16-10-2022**.

The decision of accreditation made by Pakistan National Accreditation Council implies that the organization has been found to fulfill the requirements for accreditation within the scope.

The organization however, itself is responsible for the results of performed measurements/tests.

**PAKISTAN NATIONAL ACCREDITATION COUNCIL**

**15-04-2020**

Date

\_\_\_\_\_  
Director General

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 10/08/15</b> <b>Rev. No: 07</b> <b>LAB 184</b>
---	-----------------------------------	---

**Testing Laboratory.**

Accreditation Scope of Prime Health (Pvt.) Ltd. Islamabad, Pakistan.

Permanent laboratory premises

Materials/Products tested	Testing field (e.g. environmental testing or mechanical testing)	Types of test/ Properties measured	Reference to standardized method (e.g. ISO 14577-1:2003)/ Internal method reference
Aspirin Tablets	Pharmaceutical Chemical testing	Assay of Tablets	BP-2020, Vol-3, Page # III-168
		Weight variation of Aspirin Tablets	BP-2020, Vol-5, Page # V-A408
		Identification of Aspirin Tablets	BP-2020, Vol-3, Page # III-167
		Dissolution of Aspirin Tablets	BP-2020, Vol-3, Page # III-167
		Disintegration of Aspirin Tablets	BP-2020, Vol-3, Page # V-A38

**15-04-2020**

Date

\_\_\_\_\_  
Director